<- Go Home
Gamida Cell Ltd.
Gamida Cell Ltd. researches, develops, and commercializes cell therapies. The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia. Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial. The company was incorporated in 1998 and is based in Boston, Massachusetts.
Market Cap
$2.6M
Volume
3.8M
Cash and Equivalents
$24.8M
EBITDA
-$75.2M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$6.5M
Profit Margin
241.92%
52 Week High
$2.51
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
-0.14
Price / Earnings
-0.04
Price / Tangible Book Value
-0.14
Enterprise Value
$55.9M
Enterprise Value / EBITDA
-0.77
Operating Income
-$78.2M
Return on Equity
363.56%
Return on Assets
-52.93
Cash and Short Term Investments
$24.8M
Debt
$78.1M
Equity
-$18.7M
Revenue
$2.7M
Unlevered FCF
-$48.5M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium